{"id":156478,"date":"2021-12-31T01:42:23","date_gmt":"2021-12-31T06:42:23","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19\/"},"modified":"2024-08-18T11:41:46","modified_gmt":"2024-08-18T15:41:46","slug":"revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19.php","title":{"rendered":"Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19"},"content":{"rendered":"<p><![CDATA[TORONTO, Dec.  29, 2021  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (\u201cRevive\u201d or the \u201cCompany\u201d) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company\u2019s U.S. Food & Drug Administration (\u201cFDA\u201d) Phase 3 clinical trial (the \u201cStudy\u201d) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.]]><\/p>\n<p>Go here to see the original:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2021\/12\/29\/2359021\/0\/en\/Revive-Therapeutics-Provides-Update-on-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19\">Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Go here to see the original: Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-156478","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/156478"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=156478"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/156478\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=156478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=156478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=156478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}